Select Publications
Journal articles
2018, 'Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial', The Lancet Diabetes and Endocrinology, 6, pp. 925 - 933, http://dx.doi.org/10.1016/S2213-8587(18)30289-4
,2018, 'Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop', Kidney International, 94, pp. 1053 - 1068, http://dx.doi.org/10.1016/j.kint.2018.08.018
,2018, 'Glucose lowering and the kidney: are all drug classes equal?', The Lancet Diabetes and Endocrinology, 6, pp. 835 - 837, http://dx.doi.org/10.1016/S2213-8587(18)30291-2
,2018, 'Reducing cardiovascular risk in people with diabetes and kidney disease', Medical Journal of Australia, 209, pp. 438 - 439, http://dx.doi.org/10.5694/MJA18.00929
,2018, 'New clinical trial designs for establishing drug efficacy and safety in a precision medicine era', Diabetes, Obesity and Metabolism, 20, pp. 14 - 18, http://dx.doi.org/10.1111/dom.13417
,2018, 'Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease', Cochrane Database of Systematic Reviews, 2018, http://dx.doi.org/10.1002/14651858.CD011798.pub2
,2018, 'Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials', The Lancet Diabetes and Endocrinology, 6, pp. 691 - 704, http://dx.doi.org/10.1016/S2213-8587(18)30141-4
,2018, 'Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"', Circulation, 138, pp. 660 - 661, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035717
,2018, 'Baseline characteristics and enrichment results from the SONAR trial', Diabetes, Obesity and Metabolism, 20, pp. 1829 - 1835, http://dx.doi.org/10.1111/dom.13315
,2018, 'Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease', DIABETES, 67, http://dx.doi.org/10.2337/db18-258-OR
,2018, 'Trial design innovations to accelerate therapeutic advances in chronic kidney disease: Moving from single trials to an ongoing platform', Clinical Journal of the American Society of Nephrology, 13, pp. 946 - 948, http://dx.doi.org/10.2215/CJN.01290118
,2018, 'Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review', Diabetes Research and Clinical Practice, 140, pp. 118 - 128, http://dx.doi.org/10.1016/j.diabres.2018.03.027
,2018, 'Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy', Diabetes, Obesity and Metabolism, 20, pp. 1369 - 1376, http://dx.doi.org/10.1111/dom.13245
,2018, 'Renal trials in diabetes need a platform: time for a global approach?', The Lancet Diabetes and Endocrinology, 6, pp. 356 - 358, http://dx.doi.org/10.1016/S2213-8587(17)30263-2
,2018, 'Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): A randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk', Cardiovascular Diabetology, 17, http://dx.doi.org/10.1186/s12933-018-0682-3
,2018, 'Are SGLT2 inhibitors ready for prime time for CKD?', Clinical Journal of the American Society of Nephrology, 13, pp. 318 - 320, http://dx.doi.org/10.2215/CJN.07680717
,2018, 'Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology', Kidney International Supplements, 8, pp. 82 - 89, http://dx.doi.org/10.1016/j.kisu.2017.10.012
,2018, 'Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)', Circulation, 137, pp. 323 - 334, http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032038
,2018, 'ACCORDION: Ensuring that we hear the music clearly', Clinical Journal of the American Society of Nephrology, 13, pp. 1621 - 1623, http://dx.doi.org/10.2215/CJN.11370918
,2018, 'Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS program', Circulation, 138, pp. 458 - 468, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034222
,2018, 'Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function data from the CANVAS program', Circulation, 138, pp. 1537 - 1550, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901
,2018, 'Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results from ADVANCE-ON', Diabetes Care, 41, pp. 163 - 170, http://dx.doi.org/10.2337/dc17-1467
,2018, 'New hypoglycemic agents and the kidney: What do the major trials tell us?.', F1000Research, 7, http://dx.doi.org/10.12688/f1000research.16135.1
,2018, 'The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics', American Journal of Nephrology, 46, pp. 462 - 472, http://dx.doi.org/10.1159/000484633
,2018, 'Abstract #233 Outcomes with Canagliflozin in Patients By Age Subgroups: Results from the Canvas Program', Endocrine Practice, 24, pp. 45 - 45, http://dx.doi.org/10.1016/s1530-891x(20)47079-x
,2017, 'Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Reply', NEW ENGLAND JOURNAL OF MEDICINE, 377, pp. 2099 - 2099, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000415998800023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'The authors reply', New England Journal of Medicine, 377, pp. 2099, http://dx.doi.org/10.1056/NEJMc1712572
,2017, 'Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial', Diabetes, Obesity and Metabolism, 19, pp. 1610 - 1619, http://dx.doi.org/10.1111/dom.13041
,2017, 'Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy', The Lancet, 390, pp. 1888 - 1917, http://dx.doi.org/10.1016/S0140-6736(17)30788-2
,2017, 'Action plan for optimizing the design of clinical trials in chronic kidney disease', Kidney International Supplements, 7, pp. 138 - 144, http://dx.doi.org/10.1016/j.kisu.2017.07.009
,2017, 'Closing the gap between evidence and practice in chronic kidney disease', Kidney International Supplements, 7, pp. 114 - 121, http://dx.doi.org/10.1016/j.kisu.2017.07.006
,2017, 'Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis', PLoS ONE, 12, http://dx.doi.org/10.1371/journal.pone.0184398
,2017, 'Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: Should unstable angina be included in the primary end point?', Diabetes Care, 40, pp. 1144 - 1151, http://dx.doi.org/10.2337/dc17-0068
,2017, 'Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial', Drugs in R and D, 17, pp. 441 - 448, http://dx.doi.org/10.1007/s40268-017-0201-0
,2017, 'Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data', The Lancet Diabetes and Endocrinology, 5, pp. 718 - 728, http://dx.doi.org/10.1016/S2213-8587(17)30183-3
,2017, 'Canagliflozin and cardiovascular and renal events in type 2 diabetes', New England Journal of Medicine, 377, pp. 644 - 657, http://dx.doi.org/10.1056/NEJMoa1611925
,2017, 'Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial', JAMA - Journal of the American Medical Association, 318, pp. 432 - 442, http://dx.doi.org/10.1001/jama.2017.9362
,2017, 'Reanalysis of the crystalloid versus hydroxyethyl starch trial (CHEST)', New England Journal of Medicine, 377, pp. 298 - 300, http://dx.doi.org/10.1056/NEJMc1703337
,2017, 'Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea: A systematic review and meta-analysis', JAMA - Journal of the American Medical Association, 318, pp. 156 - 166, http://dx.doi.org/10.1001/jama.2017.7967
,2017, 'Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial', Nephrology, 22, pp. 548 - 554, http://dx.doi.org/10.1111/nep.12815
,2017, 'Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials', Diabetes, Obesity and Metabolism, 19, pp. 926 - 935, http://dx.doi.org/10.1111/dom.12924
,2017, 'A trial of extending hemodialysis hours and quality of life', Journal of the American Society of Nephrology, 28, pp. 1898 - 1911, http://dx.doi.org/10.1681/ASN.2015111225
,2017, 'Chronic kidney disease in Asia: Protocol for a collaborative overview', Nephrology, 22, pp. 456 - 462, http://dx.doi.org/10.1111/nep.12821
,2017, 'Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation', American Journal of Kidney Diseases, 69, pp. 734 - 743, http://dx.doi.org/10.1053/j.ajkd.2016.10.018
,2017, 'SO019EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL', Nephrology Dialysis Transplantation, 32, pp. iii12 - iii12, http://dx.doi.org/10.1093/ndt/gfx103
,2017, 'SP259EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL', Nephrology Dialysis Transplantation, 32, pp. iii193 - iii194, http://dx.doi.org/10.1093/ndt/gfx145.sp259
,2017, 'The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy', Diabetes, Obesity and Metabolism, 19, pp. 749 - 753, http://dx.doi.org/10.1111/dom.12864
,2017, 'Comparison of exposure response relationship of atrasentan between North American and Asian populations', Diabetes, Obesity and Metabolism, 19, pp. 545 - 552, http://dx.doi.org/10.1111/dom.12851
,2017, 'Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS-R): A randomized, placebo-controlled trial', Diabetes, Obesity and Metabolism, 19, pp. 387 - 393, http://dx.doi.org/10.1111/dom.12829
,2017, 'Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients', Cochrane Database of Systematic Reviews, 2017, http://dx.doi.org/10.1002/14651858.CD009966.pub2
,